Ad is loading...
ESLA
Price
$0.89
Change
+$0.05 (+5.95%)
Updated
Nov 15 closing price
NRXS
Price
$3.15
Change
-$0.12 (-3.67%)
Updated
Nov 15 closing price
Ad is loading...

ESLA vs NRXS

Header iconESLA vs NRXS Comparison
Open Charts ESLA vs NRXSBanner chart's image
Estrella Immunopharma
Price$0.89
Change+$0.05 (+5.95%)
Volume$15.27K
CapitalizationN/A
Neuraxis
Price$3.15
Change-$0.12 (-3.67%)
Volume$7.84K
CapitalizationN/A
ESLA vs NRXS Comparison Chart
Loading...
ESLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ESLA vs. NRXS commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESLA is a Sell and NRXS is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (ESLA: $0.89 vs. NRXS: $3.15)
Brand notoriety: ESLA and NRXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ESLA: 9% vs. NRXS: 58%
Market capitalization -- ESLA: $32.21M vs. NRXS: $21.99M
ESLA [@Biotechnology] is valued at $32.21M. NRXS’s [@Biotechnology] market capitalization is $21.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESLA’s FA Score shows that 0 FA rating(s) are green whileNRXS’s FA Score has 1 green FA rating(s).

  • ESLA’s FA Score: 0 green, 5 red.
  • NRXS’s FA Score: 1 green, 4 red.
According to our system of comparison, NRXS is a better buy in the long-term than ESLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESLA’s TA Score shows that 4 TA indicator(s) are bullish.

  • ESLA’s TA Score: 4 bullish, 4 bearish.

Price Growth

ESLA (@Biotechnology) experienced а +20.27% price change this week, while NRXS (@Biotechnology) price change was +31.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

ESLA is expected to report earnings on Mar 14, 2023.

NRXS is expected to report earnings on Nov 12, 2024.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESLA($32.2M) has a higher market cap than NRXS($22M). NRXS YTD gains are higher at: 17.978 vs. ESLA (-19.820). ESLA has more cash in the bank: 4.73M vs. NRXS (1.77M).
ESLANRXSESLA / NRXS
Capitalization32.2M22M146%
EBITDAN/A-13.57M-
Gain YTD-19.82017.978-110%
P/E RatioN/AN/A-
RevenueN/A2.27M-
Total Cash4.73M1.77M268%
Total DebtN/A5.11M-
TECHNICAL ANALYSIS
Technical Analysis
ESLA
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
21%
Momentum
ODDS (%)
Bullish Trend 3 days ago
52%
MACD
ODDS (%)
Bullish Trend 3 days ago
44%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
33%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
32%
Advances
ODDS (%)
Bullish Trend 5 days ago
70%
Declines
ODDS (%)
Bearish Trend 17 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
71%
View a ticker or compare two or three
Ad is loading...
ESLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STT95.481.30
+1.38%
State Street Corp
MFIC13.750.14
+1.03%
MidCap Financial Investment Corp
WEN18.12-0.36
-1.95%
Wendy's Company
MYNZ0.24-0.01
-4.52%
Mainz Biomed NV
BAER2.97-0.43
-12.65%
Bridger Aerospace Group Holdings

ESLA and

Correlation & Price change

A.I.dvisor tells us that ESLA and WINT have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESLA and WINT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESLA
1D Price
Change %
ESLA100%
+5.95%
WINT - ESLA
26%
Poorly correlated
-3.98%
FATE - ESLA
23%
Poorly correlated
-2.88%
NRXS - ESLA
22%
Poorly correlated
-3.67%
XBIO - ESLA
22%
Poorly correlated
+0.82%
SNDX - ESLA
22%
Poorly correlated
-5.72%
More

NRXS and

Correlation & Price change

A.I.dvisor tells us that NRXS and NGNE have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NRXS and NGNE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXS
1D Price
Change %
NRXS100%
-3.67%
NGNE - NRXS
24%
Poorly correlated
-11.95%
ESLA - NRXS
22%
Poorly correlated
+5.95%
APTO - NRXS
21%
Poorly correlated
-5.28%
VTYX - NRXS
21%
Poorly correlated
-5.08%
PRAX - NRXS
20%
Poorly correlated
-6.66%
More